Maternal Determinants of Infant Immunity to Pertussis

PHASE4RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

September 12, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions
Vaccination; InfectionMaternal-Fetal RelationsPertussisImmunoglobulins
Interventions
BIOLOGICAL

Triaxis® (Pertussis-containing vaccine)

"Triaxis® (Pertussis-containing vaccine) will be administered:~* in non-pregnant women presenting to the Travel and Vaccine clinic for pertussis immunization only or hospital member staff requiring Tetanus Toxoid (TT)-booster immunisation~* in Pregnant women between 16 and 29 weeks of gestation."

BIOLOGICAL

Vaxelis® (Pertussis-containing vaccine)

Vaxelis® (Hexavalent vaccine) will be proposed in infants at 8, 12 and 16 weeks of life.

Trial Locations (1)

1000

RECRUITING

CHU Saint-Pierre, Brussels

All Listed Sponsors
collaborator

Université Libre de Bruxelles

OTHER

lead

Centre Hospitalier Universitaire Saint Pierre

OTHER